Literature DB >> 27320118

[Primary Squamous Cell Carcinoma of the Prostate in which Docetaxel Therapy was Effective : A Case Report].

Hiroyuki Moriyama1, Mitsuru Kajiwara1, Shuji Yonehara2.   

Abstract

The patient was a 73-year-old man who visited our hospital with asymptomatic gross hematuria. Cystoscopy revealed a bladder tumor in two places. Serum prostatic specific antigen was normal (2.535 ng/ml). Transurethral resection of bladder tumors was performed. In order to complete resection of bladder tumor, transurethral resection of right lobe of the prostate whitch had protruded into the bladder, was needed. Histology of the prostatic tissue revealed squamous cell carcinoma with no grandular and acinar structures. Serum SCC-antigen level was evaluated (6.2 ng/ml) after establishment of the diagnosis. Thoraco-abdominal computed tomography and 18-fluorodeoxyglucose positron emission tomography/ computed tomography ((18)F-FDG PET/CT) showed prostate cancer and multiple metastases in the lymph nodes, such as right external iliac, right common iliac, para-aortic and left supraclavicular region. The patient received external radiation therapy to the prostate and underwent systemic chemotherapy using docetaxel. After 2 courses of docetaxel therapy, multiple lymph nodes metastases were reduced and serum SCC-antigen level was normalized. Docetaxel therapy could not be continued because of a side effect of interstitial pneumonia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27320118

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient.

Authors:  Yuta Kaneko; Takeo Kosaka; Kohei Nakamura; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya
Journal:  IJU Case Rep       Date:  2022-06-24

2.  Biological role and clinical value of miR-99a-5p in head and neck squamous cell carcinoma (HNSCC): A bioinformatics-based study.

Authors:  Yu-Ting Chen; Jian-Ni Yao; Yu-Tao Qin; Kai Hu; Fang Wu; Ye-Ying Fang
Journal:  FEBS Open Bio       Date:  2018-06-26       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.